Biohaven Class Action Lawsuit: Breaking: Extremely Important and Helpful Deadline Alerts for Investors [2025]

Introduction to the Biohaven Class Action Lawsuit

Biohaven Class Action Lawsuit emerged after the company’s stock price plunged 22.61%, with shares dropping $5.38 to close at $18.42 per share on July 27, 2023. The steep decline came at the time the FDA rejected Biohaven’s troriluzole NDA. The FDA refused to review the application because Biohaven’s Phase 3 SCA Trial failed to meet its main goal.

The Biohaven Lawsuit, filed in the United States District Court for the District of Connecticut under docket number 25-cv-01120, aims to help shareholders recover their losses from alleged securities fraud. Investors who bought or acquired Biohaven’s securities between March 24, 2023 and May 14, 2025 can join this class action. The company allegedly made misleading statements about its financial health and operations that led to major financial losses for investors. Shareholders who purchased stock during this period should know their rights and recovery options before the deadline.

Please see the various investor resources below for an additional wealth of information.

Lead Plaintiff Deadlines

Investor Resources

Frequently Asked Questions

Shareholder Rights

Timeline of Events

Report a Fraud

Biohaven faces class action over failed drug trials

Biohaven‘s class action lawsuit stems from a string of failed drug trials and regulatory problems that battered the company’s stock price. The company’s shares lost 63.7% of their value between March 2023 and May 2025 as its drug candidates hit one roadblock after another.

The company’s treatment for spinocerebellar ataxia (SCA), Troriluzole, hit a major snag when its Phase 3 trial missed its main goal. Notwithstanding that, Biohaven kept talking up the drug’s chances, reassuring investors about its progress through regulatory channels. The FDA delivered a harsh blow in July 2023 by refusing to even review the New Drug Application (NDA) because of the failed endpoint.

Things got worse in March 2025. The company’s promising bipolar disorder treatment, BHV-7000, couldn’t beat a placebo in its crucial trial. Biohaven’s shares dropped 13.8% on this news. Market watchers pointed out that the drug was still being tested in other studies, and GlobalData projected possible sales of $651 million by 2030 if approved.

The bad news continued in April 2025. Biohaven pulled its troriluzole application from the European Medicines Agency (EMA). The EMA’s Committee for Medicines Products for Human Use didn’t see enough proof to back troriluzole’s “new active substance” status. The stock fell another 15.2%.

The final hit came on May 14, 2025. Biohaven announced the FDA would take three more months on the troriluzole PDUFA deadline and planned an advisory committee meeting—a sign of ongoing regulatory issues. The stock crashed 19.5% more, hitting its lowest point in 12 months.

These repeated failures are the foundations of investor claims that Biohaven misled them about its main drug candidates’ chances of success and regulatory approval.

Investors allege misleading statements by Biohaven executives

The Biohaven Class Action Lawsuit centers on serious allegations about company executives who made false and misleading statements about their main drug candidates. These misrepresentations led to artificially high stock prices that ended up causing major financial losses to investors.

The shareholders’ main claim focuses on how Biohaven officials consistently overstated troriluzole’s regulatory prospects as a treatment for spinocerebellar ataxia (SCA) and the data quality supporting its approval. The plaintiffs also claimed that executives overstated BHV-7000’s effectiveness and clinical potential as a bipolar disorder treatment.

The Biohaven Class Action Lawsuit states that defendants “made false and/or misleading statements and/or failed to disclose” vital information about these drug candidates’ true status. Investors believe the company kept them uninformed about major regulatory and clinical challenges that later crashed the stock’s value.

Legal documents show that multiple lawsuits were filed in July 2022 at the United States District Court for the Southern District of New York by stockholders. These cases included O’Dell v. Biohaven, Ranson v. Biohaven, Whitfield v. Biohaven, Hopkins v. Biohaven, Bushansky v. Biohaven, Adamson v. Biohaven, Jones v. Biohaven, and Scott v. Biohaven.

Each Biohaven Class Action Lawsuit asked for injunctive relief, more disclosures, monetary damages, and compensation for expenses. Biohaven received letters from other stockholders with similar allegations on July 15, September 15, and September 16 of 2022.

Biohaven maintains that “the claims asserted in the Actions are without merit”. The Biohaven Class Action Lawsuit explains a troubling pattern, especially when you have these alleged misrepresentations that triggered several sharp drops in stock prices during the class period.

What affected shareholders need to know before the deadline

Biohaven securities investors must act quickly. The lead plaintiff deadline for the Biohaven Class Action Lawsuit ends on September 12, 2025. This deadline marks the last chance for shareholders to ask the Court for lead plaintiff appointment.

The class action covers investors who bought or acquired Biohaven securities between March 24, 2023, and May 14, 2025. Shareholders who lost money during this timeframe can join the lawsuit.

The Private Securities Litigation Reform Act of 1995 allows any investor who bought Biohaven securities during the class period to become lead plaintiff. A lead plaintiff usually has the biggest financial stake in the outcome and guides the litigation on behalf of all class members. The chosen lead plaintiff can pick which law firm will handle the case.

Joining the Biohaven Class Action Lawsuit is simple. After registering as a BHVN shareholder from the specified period, you’ll get access to portfolio monitoring software that tracks the case’s progress.

If you suffered substantial losses and wish to serve as lead plaintiff of the Biohaven Class Action Lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com.

Lead plaintiffs must actively participate in the case, but regular class members don’t need to take action right now. You can still receive compensation without being lead plaintiff. This means you might qualify for recovery even as an absent class member if the Biohaven Class Action Lawsuit succeeds.

The Biohaven Class Action Lawsuit wants to hold the company responsible for alleged wrongdoing and get compensation for investors who lost money. You should contact one of the representing law firms to learn about your legal rights or ask questions about the case.

Conclusion

Biohaven Pharmaceuticals faces a major class action lawsuit after several drug trials failed and regulators rejected their applications. Shareholders lost nearly two-thirds of their investment value between March 24, 2023, and May 14, 2025. The company’s promising drugs troriluzole and BHV-7000 ran into serious problems that caused share prices to drop by 63.7%.

The FDA’s rejection of troriluzole’s New Drug Application shattered investor trust. The company allegedly kept promoting the drug even after its Phase 3 trial failed. Things got worse when BHV-7000 had problems and the European Medicines Agency withdrew its support.

Investors must act before the September 12, 2025 deadline if they bought Biohaven securities during this period. Lead plaintiffs need to participate actively in the case, but regular class members can receive compensation without taking charge.

This Biohaven Class Action Lawsuit shows how risky pharmaceutical investments can be and why companies must be transparent. Investors who lost money should contact the representing law firms to learn about their rights. The legal team wants to hold Biohaven accountable for misleading statements and help investors recover their losses from this regulatory mess.

Key Takeaways

Biohaven investors face critical legal deadlines and potential recovery opportunities following massive stock losses from failed drug trials and alleged corporate misrepresentations.

• Critical Deadline Alert: Investors who purchased Biohaven securities between March 24, 2023 and May 14, 2025 must act by September 12, 2025 to seek lead plaintiff status in the class action lawsuit.

• Massive Financial Impact: Biohaven’s stock plummeted 63.7% during the class period due to failed drug trials, FDA rejections, and regulatory setbacks affecting troriluzole and BHV-7000.

• Securities Fraud Allegations: The Biohaven Class Action Lawsuit claims executives made misleading statements about drug efficacy and regulatory prospects while knowing about significant clinical and regulatory challenges.

• Recovery Options Available: Affected shareholders can join the Biohaven Class Action Lawsuit without serving as lead plaintiff and may still be eligible for compensation if the case succeeds.

• Multiple Regulatory Failures: The FDA rejected troriluzole’s application outright, the EMA withdrew approval consideration, and BHV-7000 failed to show statistical separation from placebo in pivotal trials.

This case highlights the critical importance of corporate transparency in pharmaceutical investments and provides a pathway for investors to seek accountability for alleged misconduct that resulted in substantial financial losses.

Frequently Asked Questions about the Biohaven Lawsuit

Q1. What is the deadline for investors to take action in the Biohaven class action lawsuit? The deadline for affected investors to seek appointment as lead plaintiff in the Biohaven class action lawsuit is September 12, 2025.

Q2. Who is eligible to participate in the Biohaven class action lawsuit? Investors who purchased or acquired Biohaven securities between March 24, 2023, and May 14, 2025, and suffered financial losses during this period are eligible to join the Biohaven Class Action Lawsuit.

Q3. What are the main allegations in the Biohaven class action lawsuit? The lawsuit alleges that Biohaven executives made misleading statements about the efficacy and regulatory prospects of their key drug candidates, particularly troriluzole and BHV-7000, which led to significant financial losses for investors.

Q4. How much did Biohaven’s stock price decline during the class period? Biohaven’s stock price reportedly plummeted by a cumulative 63.7% between March 2023 and May 2025 due to multiple drug trial failures and regulatory setbacks.

Q5. Do I need to be a lead plaintiff to potentially receive compensation from the lawsuit? No, you don’t need to serve as a lead plaintiff to be eligible for compensation. Even as an ordinary class member, you may still be able to share in potential recovery if the lawsuit succeeds.